David Glenn 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) CFO David Glenn Sells 12,528 Shares
What Happened
David Glenn, Chief Financial Officer of Phibro Animal Health Corp (PAHC), had 30,000 restricted stock units (RSUs) settle into shares on Feb 9, 2026. To satisfy tax withholding required on the RSU vesting, 12,528 of those shares were sold in a broker-assisted cashless transaction on Feb 11, 2026 for a total of approximately $646,758 (weighted avg price $51.63).
Key Details
- Transaction dates: RSU settlement reported 2026-02-09; shares sold to cover taxes 2026-02-11 (filed 2026-02-11). Filing appears timely (within the 2-business-day window).
- Shares issued on settlement: 30,000 RSUs settled into 30,000 shares (footnote: RSUs = contingent right to one share).
- Shares sold for tax withholding: 12,528 shares disposed at a weighted average price of $51.63 (price range $51.54–$52.03).
- Net implied shares retained from this vesting event: 17,472 shares (30,000 issued − 12,528 sold), as implied by the filing.
- Footnotes: F2 confirms the sale was to satisfy tax withholding; F3 notes the reported sale price is a weighted average; F4/F5 summarize the original 300,000-RSU grant (150,000 time-vesting, 150,000 performance-vesting with a 5-year performance measure).
- Shares owned after transaction: not explicitly stated in the provided filing extract.
Context
This reporting reflects routine RSU settlement and a sale strictly to cover tax obligations (broker-assisted cashless exercise), not an open-market investment decision. For derivative/RSU items, the filing shows the conversion of RSUs to shares and the subsequent withholding sale; refer to the footnotes for grant and vesting details.
Insider Transaction Report
- Exercise/Conversion
Class A Common Stock
[F1]2026-02-09+30,000→ 64,845 total - Other
Class A Common Stock
[F2][F3]2026-02-11$51.63/sh−12,528$646,758→ 52,317 total - Exercise/Conversion
Restricted Stock Units
[F1][F4][F5]2026-02-09−30,000→ 240,000 total→ Class A Common Stock (30,000 underlying)
Footnotes (5)
- [F1]Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock.
- [F2]Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of the RSUs.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.54 to $52.03. The reporting person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").
- [F5]Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Issuer's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.